Industry Dynamics

Industry News

11-10

2022

U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients

November 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 m……

10-28

2022

AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline

Oct. 20, 2022, AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), Under the terms of the agreement, AbbVie will pay DJS shareholders approximately $255 million in cash at cl……

10-18

2022

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen by three months.……

09-30

2022

$11.6 billion! Pfizer completed its acquisition of Biohaven, a biopharmaceutical company, on October 3

Pfizer (PFE.US) 's $22.6 billion acquisition of Biohaven (BHVN.US) will be completed on October 3, according to the Securities and Exchange Commission.Pfizer announced plans to acquire Biohaven in May. After the acqu……

09-12

2022

Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

September 5, 2022 --AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) declin……

08-31

2022

FDA Approves Auvelity FDA Approves Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder in Adults

NEW YORK, August 29, 2022 (GLOBE NEWSWIRE) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, t……

< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 >

Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1